NRXP
NRX Pharmaceuticals Inc
3.00$
-4.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | – | – | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 12.5% | 12.5% | – | – | 25.0% | 50.0% | – | 57.0% | 51.7% | 74.5% | 76.6% | 67.3% | |
| – | -12.5% | -12.5% | – | – | -25.0% | 50.0% | – | 43.0% | 48.3% | 25.5% | 23.4% | 32.7% | |
| – | 31,675.0% | 21,850.0% | – | – | 25,900.0% | 20,100.0% | – | 590.5% | 56.8% | 122.6% | 192.2% | 159.5% | |
| – | 23,400.0% | 53,125.0% | – | – | 64,950.0% | 73,575.0% | – | 1,160.3% | 464.8% | 357.0% | 431.0% | 469.5% | |
| – | 55,062.5% | 74,962.5% | – | – | 90,825.0% | 96,175.0% | – | 1,744.6% | 515.7% | 470.0% | 614.3% | 620.9% | |
| – | -55,075.0% | -74,975.0% | – | – | -90,850.0% | -96,175.0% | – | -1,701.7% | -467.3% | -444.6% | -590.8% | -588.2% | |
| – | 1,000.0% | 2,875.0% | – | – | 0.0% | 0.0% | – | 0.0% | 68.3% | 21.8% | 21.8% | 33.7% | |
| – | -54,150.0% | -81,600.0% | – | – | -226,950.0% | -137,800.0% | – | -2,433.9% | 36.6% | -133.9% | -1,500.5% | -691.8% | |
| – | -17,425.0% | -528.5% | – | – | – | – | – | – | – | – | – | – | |
| – | -54,150.0% | -81,600.0% | – | – | -226,950.0% | -137,800.0% | – | -2,433.9% | 36.6% | -133.9% | -1,500.5% | -691.8% | |
| – | -53,137.5% | -78,712.5% | – | – | -226,925.0% | -137,775.0% | – | -2,416.9% | 115.1% | -96.6% | -1,472.7% | -647.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.